The long-term prospects for the company are evolving with product approvals in China, build-up of consumer healthcare franchise, and a biosimilar pipeline.

Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity but without diabetes, according to a study published online Jan. 21 in JAMA Network ...

Revlimid, which has arguably been the single biggest growth driver for Dr Reddy's in recent years, is set to go off patent in ...

A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.

A California couple is suing JetBlue for $1 million over a massive chunk of ice crashed through their bedroom from one of its ...

Extending losses for the second session, Dr Reddy’s shares dropped 6.65% to hit a low of ₹1,203.60 on the BSE as investors weighed weak Q3 results.

Semaglutide is a powerful aid for managing weight and Type 2 diabetes, but it’s not a free pass to stick with old habits—or skip taking action altogether. If you’ve been struggling with weight loss, ...

Dr. Reddy’s is focusing on a pipeline of complex drugs, including GLP-1s (such as Semaglutide) as well as biosimilars and consumer care to offset the loss of exclusivity for its blockbuster drug ...

Dr Reddy’s shares tumbled up to 6% in early trade and at 9:46 am, they were trading 4.35% lower at Rs 1,233.25 on the Bombay Stock Exchange (BSE).

Shares of Dr Reddy's Laboratories Ltd tumbled more than 6.65 per cent to Rs 1,203.60 on Friday, with its total market capitalisation slipping below Rs 1 lakh crore mark.

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon confirm that.